Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies, Ltd., says that tumor-derived chaperone-rich cell lysate (CRCL), which is composed of various heat shock proteins, has been successfully used to produce tumor-specific T-cell responses and protective immunity against a wide variety of murine tumors. Dr. Michael Har-Noy says that investigators have also examined the ability of CRCL derived from human ovarian cancer cells to activate dendritic cells and to stimulate the production of in vitro tumor-specific T-cells.
CRCL was produced from ovarian tumors and the SKOV3-A2 ovarian cancer cell line. Dr. Michael Har-Noy noted that peripheral blood mononucleocytes from both HLA-A2+ healthy donors and HLA-A2+ ovarian cancer patients were stimulated every week with autologous dendritic cells heavily laden with CRCL derived from ovarian tumor cells. Following four to six in vitro stimulations, cytokine secretion and cytotoxicity were specifically measured.
Dr. Michael Har-Noy noted that CRCL stimulation increased the amount of interleukin (IL)-12 secretion and augmented the immune-stimulatory ability of the dendritic cells. Also, T-cells from healthy controls and from patients with ovarian cancer both secreted larger quantities of interferon-g after in vitro re-stimulation with ovarian cancer-derived CRCL than after stimulation with HER2/neu or WT1 peptide-pulsed dendritic cells.
Dr. Michael Har-Noy points out that the investigators were able to generate cytotoxic T-lymphocyte activity against cancer specific antigens from all of healthy donors, but from only 25% of the patients with advanced ovarian cancer in the absence of CRCL stimulation. Dr. Michael Har-Noy concludes that these results further substantiate the idea that CRCL will likely be an effective treatment for women suffering from ovarian cancer and that this individualized vaccine will yield promising new approaches for cancer immunotherapy.
Dr. Michael Har-Noy is now conducting a Phase I/II trial of the CRCL vaccine in various solid tumors. He is conducting the study in Bangkok, Thailand, and has combined it with a Compassionate Use program. Dr. Michael Har-Noy indicates that detailed information can be found at www.immunocare.net.